E L Pritchett

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Evolution and revolution in drug labeling: regulation of antiarrhythmic drugs by the Food and Drug Administration 1962-1996
    E L Pritchett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pacing Clin Electrophysiol 21:1457-69. 1998
  2. ncbi Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators
    E L Pritchett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 36:794-802. 2000
  3. ncbi Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics
    R L Page
    Department of Medicine, Duke University Medical Center, Durham, NC 27710
    Clin Pharmacol Ther 51:371-8. 1992
  4. ncbi Observations on the transition from intermittent to permanent atrial fibrillation
    S M Al-Khatib
    Divisions of Clinical Pharmacology and Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 140:142-5. 2000
  5. ncbi Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias
    E L Pritchett
    Department of Medicine Division of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina
    Am J Cardiol 67:976-80. 1991

Collaborators

Detail Information

Publications5

  1. ncbi Evolution and revolution in drug labeling: regulation of antiarrhythmic drugs by the Food and Drug Administration 1962-1996
    E L Pritchett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pacing Clin Electrophysiol 21:1457-69. 1998
    ..The FDA, the scientific community, and the pharmaceutical industry have all participated in and been affected by this evolution in drug development...
  2. ncbi Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators
    E L Pritchett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 36:794-802. 2000
    ..The purpose of this study was to assess the effectiveness of azimilide, a class III antiarrhythmic drug, in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation, atrial flutter or both...
  3. ncbi Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics
    R L Page
    Department of Medicine, Duke University Medical Center, Durham, NC 27710
    Clin Pharmacol Ther 51:371-8. 1992
    ..12, 1.77, and 12.3 hours, respectively. The mean absolute oral bioavailability was 43%...
  4. ncbi Observations on the transition from intermittent to permanent atrial fibrillation
    S M Al-Khatib
    Divisions of Clinical Pharmacology and Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 140:142-5. 2000
    ....
  5. ncbi Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias
    E L Pritchett
    Department of Medicine Division of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina
    Am J Cardiol 67:976-80. 1991
    ..6 with a 95% confidence interval of 0.2, 1.7. These descriptive comparisons did not demonstrate any excess mortality when flecainide and encainide were used in patients with supraventricular arrhythmias...